Addressing Diagnostic Challenges for Non-Alcoholic Steatohepatitis (NASH)

PFIZER, S.A

Objecte

Topic: Non-Alcoholic Steatohepatitis (NASH).

Destination: It is their intent to provide an independent grant(s) to an organization or organizations that will focus on developing educational programs to help inform about the diagnosis of NASH beyond biopsy by applying non-invasive tools for NASH and the use of real-world data to develop predictive models that identify the patients at risk of progressing into advanced stages of liver disease. Projects that will be considered for Pfizer support will focus on:
• dissemination of information related to current and innovative non-invasive tools in-development to diagnose and monitor NASH
• increasing awareness of the added value of real-word evidence to address gaps in patient screening, identification and how they could support of the proper diagnosis of NASH
The submitted proposals should aim to inform the scientific and clinical community and to advance the discussion around management of liver and cardiovascular outcomes in NASH.

Budget: $250,000.

Duration: Up to 2 years.

Are you interested in this call?

Estàs interessat?

Omple el següent formulari per rebre més informació: